111 related articles for article (PubMed ID: 22248236)
1. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
Kettle JG; Brown S; Crafter C; Davies BR; Dudley P; Fairley G; Faulder P; Fillery S; Greenwood H; Hawkins J; James M; Johnson K; Lane CD; Pass M; Pink JH; Plant H; Cosulich SC
J Med Chem; 2012 Feb; 55(3):1261-73. PubMed ID: 22248236
[TBL] [Abstract][Full Text] [Related]
2. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.
Lin H; Yamashita DS; Zeng J; Xie R; Verma S; Luengo JI; Rhodes N; Zhang S; Robell KA; Choudhry AE; Lai Z; Kumar R; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):679-83. PubMed ID: 20005102
[TBL] [Abstract][Full Text] [Related]
3. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.
Stec MM; Andrews KL; Booker SK; Caenepeel S; Freeman DJ; Jiang J; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Yang K; Zalameda LP; Zhang N; Hughes PE; Norman MH
J Med Chem; 2011 Jul; 54(14):5174-84. PubMed ID: 21714526
[TBL] [Abstract][Full Text] [Related]
5. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
8. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
[TBL] [Abstract][Full Text] [Related]
9. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
[TBL] [Abstract][Full Text] [Related]
10. Nanomolar inhibitors of Mycobacterium tuberculosis glutamine synthetase 1: synthesis, biological evaluation and X-ray crystallographic studies.
Couturier C; Silve S; Morales R; Pessegue B; Llopart S; Nair A; Bauer A; Scheiper B; Pöverlein C; Ganzhorn A; Lagrange S; Bacqué E
Bioorg Med Chem Lett; 2015 Apr; 25(7):1455-9. PubMed ID: 25770781
[TBL] [Abstract][Full Text] [Related]
11. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
12. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Zambon A; Ménard D; Suijkerbuijk BM; Niculescu-Duvaz I; Whittaker S; Niculescu-Duvaz D; Nourry A; Davies L; Manne HA; Lopes F; Preece N; Hedley D; Ogilvie LM; Kirk R; Marais R; Springer CJ
J Med Chem; 2010 Aug; 53(15):5639-55. PubMed ID: 20597484
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
Wu CH; Coumar MS; Chu CY; Lin WH; Chen YR; Chen CT; Shiao HY; Rafi S; Wang SY; Hsu H; Chen CH; Chang CY; Chang TY; Lien TW; Fang MY; Yeh KC; Chen CP; Yeh TK; Hsieh SH; Hsu JT; Liao CC; Chao YS; Hsieh HP
J Med Chem; 2010 Oct; 53(20):7316-26. PubMed ID: 20961149
[TBL] [Abstract][Full Text] [Related]
14. Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Rice KD; Kim MH; Bussenius J; Anand NK; Blazey CM; Bowles OJ; Canne-Bannen L; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Klein RR; Laird AD; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W
Bioorg Med Chem Lett; 2012 Apr; 22(8):2693-7. PubMed ID: 22450127
[TBL] [Abstract][Full Text] [Related]
15. Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators.
Hong SP; Liu KG; Ma G; Sabio M; Uberti MA; Bacolod MD; Peterson J; Zou ZZ; Robichaud AJ; Doller D
J Med Chem; 2011 Jul; 54(14):5070-81. PubMed ID: 21688779
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
[TBL] [Abstract][Full Text] [Related]
17. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
[TBL] [Abstract][Full Text] [Related]
18. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
Zak M; Hurley CA; Ward SI; Bergeron P; Barrett K; Balazs M; Blair WS; Bull R; Chakravarty P; Chang C; Crackett P; Deshmukh G; DeVoss J; Dragovich PS; Eigenbrot C; Ellwood C; Gaines S; Ghilardi N; Gibbons P; Gradl S; Gribling P; Hamman C; Harstad E; Hewitt P; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Labadie S; Lee WP; Liao J; Liimatta M; Mendonca R; Narukulla R; Pulk R; Reeve A; Savage S; Shia S; Steffek M; Ubhayakar S; van Abbema A; Aliagas I; Avitabile-Woo B; Xiao Y; Yang J; Kulagowski JJ
J Med Chem; 2013 Jun; 56(11):4764-85. PubMed ID: 23659214
[TBL] [Abstract][Full Text] [Related]
19. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
[TBL] [Abstract][Full Text] [Related]
20. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]